PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|February 11, 2016
GRAM Completes Fourth FDA Inspection
Author(s)Pharmaceutical Technology Editors
GRAM completed a fourth FDA inspection of its parenteral manufacturing facility with no Form 483 observation issues.
Advertisement
Grand River Aseptic Manufacturing (GRAM) announced on Feb. 10, 2016 the competition of its fourth FDA inspection of its contract parenteral manufacturing facility in Grand Rapids, MI.
The seven-day inspection included a general GMP and a pre-approval inspection. FDA found GRAM to be in compliance with the current good manufacturing practices (cGMP) and passed pre-approval inspection, with no Form 483 observation issues. According to FDA, Form 483 is issued at the conclusion of inspections if the investigators discover violations of the Food Drug and Cosmetic Act and related acts.
GRAM is a parenteral contract manufacturing organization focused on cGMP manufacturing and new product development. The company specializes in preclinical, clinical, and commercial manufacturing.
Source: GRAM
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement